Introduction {#s00}
============

Colorectal cancer (CRC) is a common malignant gastrointestinal cancer in China. It was shown in the latest data released by the National Cancer Center in 2017 that CRC ranked the fourth in terms of incidence of malignant tumors and the fifth in terms of death rate ([@b1]). In 2018, nearly two million newly diagnosed CRC cases and over 800,000 CRC related deaths are expected worldwide ([@b2]). CRC incidence and death rates have been stabilizing or decreasing in highly developed countries through the enormous efforts over the last decades ([@b3]). However, a rapid growth of CRC has been seen in many low-income and middle-income countries ([@b4]).

As one of the largest developing countries, China has been experiencing a rapid economic growth and health care reform. The diet and other factors related to CRC risk are also changing rapidly in China. One of the major public health issues is the rapid growth in CRC incidence and the accompanying increase in disease burden ([@b5],[@b6]). According to the data from the National Central Cancer Registry (NCCR) of China, it was estimated that there were 274,841 new CRC cases (157,355 males and 117,486 females) diagnosed in 2010, which accounted for nearly one tenth of the global CRC burden in that year ([@b7]). Therefore, it is urgent to understand the epidemiological trends of CRC in China, so that related health policies accommodated to the trend of CRC prevalence, including prevention and management of cancer, can be established as soon as possible to improve public health.

Data were obtained from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease (GBD) (https://vizhub.healthdata.org). The sample size of the data about the CRC related death, incidence and prevalence was large and provided a solid base for the analysis. By analyzing the data, we can see what is the ranking and distribution of CRC deaths of China in the world. The results obtained from our study should be useful for understanding CRC better, evaluating current prevention strategies, planning to manage disease burden national wide, and improving health management system to meet future challenges.

Materials and methods {#s01}
=====================

Data sources {#s01.01}
------------

Death, incidence and prevalence data were extracted from the official website of GBD 2017 Study led by IHME for free. The GBD is hierarchically organized by geographic units or locations, with 7 super-regions, 21 regions nested within these super-regions, and 195 countries or territories within 21 regions. In the GBD Study, 95% uncertainty intervals (95% UIs) were determined based on the 25th and 975th ranked values across all 1,000 draws ([@b8]). Uncertainty analysis is the estimation of range or distribution of uncertainty in estimates based on an assessment of the uncertainty or confidence intervals for all data and parameter inputs. UIs should ideally include all sources of uncertainty, including those arising from systematic biases and measurement error. In contrast, generally reported confidence intervals are based solely on the variation observed in sample data ([@b9]).

In the database, we chose "China" for the location, "colon and rectum cancer" for cause, and "death", "incidence" and "prevalence" for measures. The cause of death attributed each death to a single underlying cause that began the series of events leading to death, in accordance with International Classification of Diseases (ICD) 10 principles. The GBD study organized causes of death in a hierarchical list containing four levels, and the cause of colon and rectum cancer was in level 3 which represented the finest level of detail by cause, such as CRC, stomach cancer or stroke.

In the GBD study, the causes of death database of IHEM includes vital registration (VR), verbal autopsy (VA), registry, survey, police and surveillance data ([@b10]). Non-fatal estimation began with the compilation of data sources from a diverse set of possible sources, including 21 possible Global Health Data Exchange (GHDx) data types such as scientific literature, survey data and epidemiological surveillance data ([@b11]).

Statistical analysis {#s01.02}
--------------------

Descriptive analysis was conducted on CRC death, incidence and prevalence data by gender, age and year. Age grouping was based on the GBD 2017 published data. Three rough age groups (15−49 years old, 50−69 years old and 70+ years old) were used to analyze the time trend of CRC. Cases were age-grouped by every 5 years in the detailed descriptions of death, incidence and prevalence of CRC in 2017. Since the death, incidence and prevalence rates of CRC were zero for those patients younger than 15 years old, the groups of 0−4 years old, 5−9 years old and 10−14 years old were combined to a single age group. The changes of each parameter were calculated by comparing the data of year 2017 to the data of year 1990.

Results {#s02}
=======

Trend of CRC death, incidence and prevalence over time {#s02.01}
------------------------------------------------------

The death rate of CRC was 13.24/100,000 (95% UI: 12.53, 13.84) in China in 2017 (*[Figure 1](#Figure1){ref-type="fig"}*, *[Supplementary Table S1](#TableS1){ref-type="table"}*), we present the death rate, incidence and prevalence rate of CRC in China by gender and age in 2017 (*[Table 1](#Table1){ref-type="table"}*). From the geographical distribution of CRC deaths in *[Figure 1](#Figure1){ref-type="fig"}*, we can see that China's CRC deaths are obviously higher than those of South Asia and Africa, but significantly lower than those of developed countries such as Europe and the United States. CRC of China ranked 21st among all causes of death in 1990, while ranked 11th in 2017 (*[Figure 2](#Figure2){ref-type="fig"}*). The death, incidence and prevalence rates of CRC were standardized by age scale of global population in 2010. The standardized death rate of CRC increased from 9.33/100,000 in 1990 (8.78−10.29) to 10.10/100,000 in 2017 (9.57−10.55) (*[Figure 3](#Figure3){ref-type="fig"}*), which was not statistically significant. The standardized death rate of CRC was slightly higher in male than in female in 1990 (10.37/100,000 *vs*. 8.53/100,000). In contrast, the standardized death rate of CRC in male obviously increased as compared to that in female in 2017 (12.48/100,000 *vs*. 7.98/100,000). The standardized incidence rate of CRC increased from 12.18/100,000 (11.45−13.41) in 1990 to 22.42/100,000 (95% UI: 21.20, 23.49) in 2017. The standardized incidence rate of CRC was similar in male and in female in 1990 (13.35/100,000*vs*. 11.23/100,000). In contrast, the standardized incidence rate of CRC in male obviously increased as compared to that in female in 2017 (27.67/100,000 *vs*. 17.56/100,000) (*[Table 2](#Table2){ref-type="table"}*). The standardized prevalence rate of CRC significantly increased from 44.55/100,000 (95% UI: 41.98, 48.69) in 1990 to 118.40/100,000 (95% UI: 111.92, 124.17) in 2017 for both genders, and it was slightly higher in male than in female in 1990 (47.47/100,000 *vs*. 42.10/100,000). Similar to incidence rate, the standardized prevalence rate of CRC was obviously higher than in male than in female in 2017 (143.20/100,000 *vs*. 94.53/100,000) (*[Figure 4](#Figure4){ref-type="fig"}*).

![Geographical distribution of death rate per 100,000 colorectal cancer cases worldwide in 2017.](cjcr-31-3-489-1){#Figure1}

###### 

Death rate of CRC in China, 1990−2017 (per 100,000)

  Year   Both genders (95% UI)   Male (95% UI)          Female (95% UI)
  ------ ----------------------- ---------------------- ----------------------
  1990   6.34 (5.96, 6.98)       6.45 (6.05, 6.97)      6.22 (5.66, 7.25)
  1991   6.48 (6.12, 7.10)       6.62 (6.25, 7.10)      6.32 (5.81, 7.33)
  1992   6.58 (6.24, 7.18)       6.75 (6.41, 7.19)      6.40 (5.93, 7.34)
  1993   6.65 (6.35, 7.24)       6.83 (6.50, 7.23)      6.47 (6.04, 7.38)
  1994   6.71 (6.43, 7.30)       6.89 (6.58, 7.26)      6.51 (6.11, 7.36)
  1995   6.80 (6.56, 7.34)       7.03 (6.73, 7.40)      6.56 (6.21, 7.30)
  1996   6.91 (6.68, 7.40)       7.17 (6.87, 7.55)      6.63 (6.32, 7.28)
  1997   7.02 (6.81, 7.44)       7.31 (7.00, 7.67)      6.72 (6.42, 7.29)
  1998   7.16 (6.95, 7.54)       7.49 (7.19, 7.87)      6.80 (6.52, 7.34)
  1999   7.27 (7.06, 7.65)       7.66 (7.35, 8.03)      6.85 (6.58, 7.34)
  2000   7.40 (7.18, 7.78)       7.88 (7.58, 8.26)      6.88 (6.60, 7.37)
  2001   7.57 (7.37, 7.91)       8.13 (7.82, 8.49)      6.99 (6.72, 7.41)
  2002   7.84 (7.64, 8.16)       8.50 (8.18, 8.90)      7.14 (6.87, 7.54)
  2003   8.12 (7.91, 8.45)       8.94 (8.57, 9.38)      7.26 (6.98, 7.69)
  2004   8.39 (8.16, 8.71)       9.31 (8.93, 9.72)      7.42 (7.14, 7.84)
  2005   8.57 (8.36, 8.82)       9.51 (9.16, 9.83)      7.57 (7.32, 7.92)
  2006   8.75 (8.56, 8.95)       9.73 (9.32, 10.03)     7.73 (7.51, 7.97)
  2007   9.06 (8.79, 9.27)       10.15 (9.61, 10.52)    7.92 (7.70, 8.14)
  2008   9.47 (9.17, 9.68)       10.69 (10.12, 11.04)   8.19 (7.94, 8.43)
  2009   9.92 (9.62, 10.13)      11.27 (10.65, 11.61)   8.49 (8.25, 8.74)
  2010   10.33 (10.02, 10.58)    11.83 (11.20, 12.20)   8.76 (8.51, 9.04)
  2011   10.76 (10.44, 11.01)    12.32 (11.74, 12.72)   9.13 (8.84, 9.44)
  2012   11.17 (10.80, 11.44)    12.77 (12.17, 13.22)   9.49 (9.18, 9.85)
  2013   11.44 (11.02, 11.76)    13.02 (12.40, 13.52)   9.78 (9.37, 10.16)
  2014   12.01 (11.62, 12.37)    13.74 (13.07, 14.29)   10.21 (9.80, 10.63)
  2015   12.67 (12.21, 13.08)    14.60 (13.83, 15.26)   10.65 (10.21, 11.15)
  2016   13.14 (12.60, 13.62)    15.21 (14.30, 16.01)   10.99 (10.49, 11.54)
  2017   13.24 (12.53, 13.84)    15.30 (14.18, 16.19)   11.10 (10.30, 11.85)

###### 

Death rate, incidence and prevalence rate of CRC in China by gender and age in 2017 (per 100,000)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age (year)   Death rate (95% UI)                      Prevalence rate (95% UI)      Incidence rate (95% UI)                                                                                    
  ------------ --------------------- ------------------ -------------------------- -- ------------------------- -------------------- ------------------ -- ------------------ ------------------ ------------------
  0−14         0                     0                  0                             0                         0                    0                     0                  0                  0

  15−19        0.11\                 0.13\              0.08\                         2.27\                     2.70\                1.78\                 0.36\              0.43\              0.28\
               (0.10, 0.12)          (0.12, 0.16)       (0.07, 0.10)                  (2.02, 2.53)              (2.33, 3.16)         (1.47, 2.09)          (0.32, 0.40)       (0.37, 0.50)       (0.23, 0.33)

  20−24        0.23\                 0.26\              0.20\                         5.83\                     6.44\                5.19\                 0.89\              0.99\              0.79\
               (0.20, 0.26)          (0.22, 0.30)       (0.16, 0.24)                  (5.07, 6.51)              (5.54,7.53)          (4.02, 6.15)          (0.77, 1.00)       (0.85, 1.15)       (0.61, 0.94)

  25−29        0.69\                 0.80\              0.58\                         20.93\                    23.75\               18.06\                3.16\              3.60\              2.71\
               (0.63, 0.74)          (0.71, 0.88)       (0.52, 0.65)                  (19.30, 22.49)            (20.93, 26.23)       (15.84, 20.11)        (2.91, 3.39)       (3.17, 3.96)       (2.38, 3.02)

  30−34        1.30\                 1.48\              1.11\                         35.79\                    40.26\               31.20\                5.46\              6.16\              4.74\
               (1.19, 1.40)          (1.33, 1.63)       (0.98, 1.23)                  (32.81, 38.60)            (35.51, 44.44)       (27.44, 34.79)        (5.01, 5.89)       (5.42, 6.80)       (4.16, 5.28)

  35−39        1.76\                 2.00\              1.52\                         44.19\                    49.44\               38.75\                6.70\              7.52\              5.84\
               (1.61, 1.90)          (1.79, 2.21)       (1.32, 1.69)                  (40.11, 47.93)            (44.00, 54.75)       (33.82, 43.29)        (6.08, 7.26)       (6.69, 8.34)       (5.09, 6.53)

  40−44        3.06\                 3.52\              2.57\                         70.34\                    81.12\               59.15\                10.61\             12.26\             8.90\
               (2.81, 3.26)          (3.16, 3.83)       (2.29, 2.83)                  (64.52, 75.43)            (72.23, 88.85)       (52.38, 65.55)        (9.73, 11.38)      (10.95, 13.43)     (7.87, 9.87)

  45−49        6.45\                 7.75\              5.09\                         128.31\                   153.75\              101.91\               19.91\             23.95\             15.71\
               (6.03, 6.85)          (7.05, 8.43)       (4.63, 5.54)                  (119.79, 136.45)          (139.60, 167.80)     (92.08, 110.54)       (18.57, 21.18)     (21.76, 26.19)     (14.17, 17.06)

  50−54        10.92\                13.44\             8.37\                         216.31\                   261.00\              171.26\               33.66\             40.98\             26.27\
               (10.22, 11.60)        (12.23, 14.61)     (7.75, 9.02)                  (202.25, 230.80)          (236.53, 285.36)     (157.20, 186.05)      (31.45, 35.88)     (37.08, 44.69)     (24.11, 28.58)

  55−59        13.90\                17.39\             10.35\                        267.02\                   329.86\              202.84\               41.81\             52.09\             31.31\
               (13.08, 14.71)        (15.95, 18.75)     (9.53, 11.13)                 (250.57, 283.31)          (299.60, 358.68)     (185.62, 220.03)      (39.19, 44.37)     (47.32, 56.60)     (28.65, 33.96)

  60−64        28.31\                35.45\             21.12\                        486.13\                   596.47\              375.04\               79.02\             98.20\             59.71\
               (26.70, 30.02)        (32.70, 38.16)     (19.38, 22.80)                (457.09, 516.26)          (545.65, 642.89)     (341.25, 408.01)      (74.26, 83.86)     (89.94, 105.90)    (54.28, 64.99)

  65−69        47.22\                59.46\             35.35\                        708.73\                   872.01\              550.31\               121.78\            152.58\            91.90\
               (44.31, 49.76)        (54.35, 63.79)     (32.50, 38.14)                (663.22, 750.23)          (794.80, 943.63)     (502.82, 597.25)      (113.77, 128.92)   (138.88, 165.04)   (83.88, 99.66)

  70−74        62.41\                76.26\             49.14\                        749.72\                   894.73\              610.75\               140.89\            171.89\            111.18\
               (58.42, 65.73)        (70.32, 81.73)     (44.79, 53.11)                (700.57, 792.70)          (821.10, 964.81)     (555.73, 663.97)      (131.45, 148.85)   (157.60, 185.40)   (101.09, 121.02)

  75−79        93.72\                115.30\            73.65\                        791.87\                   958.23\              637.15\               175.43\            217.01\            136.75\
               (88.21, 98.56)        (106.27, 123.41)   (67.40, 79.15)                (745.14, 834.94)          (885.52, 1,026.92)   (584.29, 685.99)      (164.93, 185.04)   (200.25, 233.01)   (124.84, 147.38)

  80−84        132.85\               162.73\            108.52\                       529.65\                   647.18\              433.93\               175.41\            220.32\            138.84\
               (123.72, 139.09)      (149.34, 173.48)   (99.56, 116.11)               (494.24, 555.36)          (592.05, 691.72)     (398.04, 464.65)      (163.40, 184.23)   (202.05, 235.80)   (126.71, 149.24)

  85−89        161.51\               197.76\            136.98\                       568.44\                   692.81\              484.32\               213.76\            269.37\            176.14\
               (153.23, 169.23)      (182.54, 210.44)   (127.84, 146.13)              (537.52, 596.89)          (631.64, 738.64)     (452.79, 515.08)      (202.34, 225.01)   (246.42, 288.27)   (163.90, 187.88)

  90−94        173.06\               228.98\            144.66\                       515.11\                   673.09\              434.90\               229.39\            312.39\            187.25\
               (164.47, 181.03)      (210.83, 246.58)   (135.60, 153.60)              (491.05, 539.24)          (623.37, 722.50)     (408.26, 461.39)      (218.15, 240.59)   (288.06, 336.49)   (175.03, 199.39)

  95+          171.57\               235.50\            148.34\                       190.06\                   257.15\              165.69\               226.80\            321.98\            192.21\
               (161.84, 181.63)      (214.35, 255.39)   (137.61, 160.24)              (180.23, 200.38)          (237.76, 276.24)     (155.17, 177.00)      (212.98, 240.77)   (292.06, 352.57)   (178.02, 208.09)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Ranking of death rates for death-related causes in China. Both genders and all age groups were included. Top 25 causes of death and their corresponding ranking order in 1990 and in 2017 were shown.](cjcr-31-3-489-2){#Figure2}

![Age-standardized death rate of colorectal cancer (CRC) in both genders, male and female only. Results were obtained from the data of Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease (GBD) from 1990 to 2017 (per 100,000).](cjcr-31-3-489-3){#Figure3}

###### 

Age-standardized incidence rate of CRC in China, 1990−2017 (per 100,000)

  Year   Both genders (95% UI)   Male (95% UI)          Female (95% UI)
  ------ ----------------------- ---------------------- ----------------------
  1990   12.18 (11.45, 13.41)    13.35 (12.48, 14.43)   11.23 (10.24, 13.04)
  1991   12.36 (11.68, 13.53)    13.58 (12.81, 14.55)   11.36 (10.46, 13.07)
  1992   12.45 (11.83, 13.59)    13.71 (12.99, 14.60)   11.41 (10.59, 13.02)
  1993   12.49 (11.93, 13.57)    13.74 (13.03, 14.57)   11.45 (10.70, 12.98)
  1994   12.49 (11.97, 13.53)    13.74 (13.08, 14.48)   11.43 (10.73, 12.84)
  1995   12.57 (12.13, 13.52)    13.90 (13.27, 14.65)   11.44 (10.84, 12.68)
  1996   12.70 (12.29, 13.57)    14.09 (13.46, 14.78)   11.51 (10.98, 12.59)
  1997   12.81 (12.42, 13.56)    14.25 (13.61, 14.92)   11.58 (11.08, 12.53)
  1998   12.95 (12.58, 13.63)    14.49 (13.86, 15.21)   11.63 (11.14, 12.49)
  1999   13.01 (12.64, 13.65)    14.66 (14.07, 15.35)   11.59 (11.12, 12.35)
  2000   13.12 (12.75, 13.77)    14.94 (14.34, 15.63)   11.53 (11.08, 12.25)
  2001   13.37 (13.02, 13.93)    15.35 (14.75, 16.05)   11.64 (11.20, 12.27)
  2002   13.81 (13.45, 14.33)    16.05 (15.42, 16.78)   11.85 (11.39, 12.47)
  2003   14.30 (13.91, 14.83)    16.90 (16.17, 17.71)   12.02 (11.55, 12.67)
  2004   14.76 (14.37, 15.26)    17.60 (16.83, 18.37)   12.25 (11.79, 12.91)
  2005   15.03 (14.68, 15.48)    17.94 (17.25, 18.56)   12.46 (12.04, 12.98)
  2006   15.33 (14.95, 15.69)    18.31 (17.45, 18.90)   12.70 (12.34, 13.09)
  2007   15.89 (15.38, 16.28)    19.14 (18.05, 19.86)   13.03 (12.66, 13.41)
  2008   16.69 (16.11, 17.08)    20.25 (19.06, 20.94)   13.53 (13.11, 13.93)
  2009   17.51 (16.93, 17.91)    21.38 (20.13, 22.05)   14.06 (13.65, 14.48)
  2010   18.27 (17.68, 18.71)    22.48 (21.15, 23.23)   14.52 (14.06, 14.98)
  2011   18.95 (18.34, 19.41)    23.28 (22.01, 24.08)   15.05 (14.56, 15.60)
  2012   19.61 (18.95, 20.12)    24.03 (22.86, 24.90)   15.59 (15.01, 16.19)
  2013   20.10 (19.33, 20.69)    24.50 (23.24, 25.44)   16.06 (15.35, 16.72)
  2014   21.02 (20.29, 21.66)    25.68 (24.33, 26.77)   16.69 (15.99, 17.44)
  2015   21.97 (21.19, 22.73)    27.00 (25.54, 28.21)   17.28 (16.52, 18.12)
  2016   22.54 (21.62, 23.41)    27.82 (26.06, 29.27)   17.63 (16.74, 18.56)
  2017   22.42 (21.20, 23.49)    27.67 (25.57, 29.33)   17.56 (16.21, 18.72)

![Age-standardized prevalence rate of colorectal cancer (CRC) in both genders, male and female only. Results were obtained from the data of Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease (GBD) from 1990 to 2017 (per 100,000).](cjcr-31-3-489-4){#Figure4}

Gender differences of CRC death and prevalence in different age groups {#s02.02}
----------------------------------------------------------------------

The death and prevalence data of CRC in 1990 were compared to those data in 2017 in age groups of 15−49 years old, 50−69 years old and 70+ years old (*[Figure 5](#Figure5){ref-type="fig"}*). The results revealed a higher prevalence rate of CRC in both genders in all three age groups in 2017 (141.6%, 209.8% and 189.0%, respectively), while the death rate of CRC increased in age groups older than 50 years in both genders (8.6% in 50−69 year-old group and 31.0% in 70+ year-old group), but decreased in 15−49 year-old group (−10.8%).

![Comparison of age-related death rate and prevalence rate of colorectal cancer (CRC) between 1990 and 2017. Data were presented in both genders (A), male only (B) and female only (C).](cjcr-31-3-489-5){#Figure5}

We then analyzed the data based on gender of patients. The result showed that the prevalence rate of CRC in male grew higher in 2017 compared to that in 1990 in all three age groups (171.2%, 265.8% and 215.0%, respectively), the death rate of CRC increased in age groups older than 50 years (28.3% in 50−69 year-old group and 40.5% in 70+ year-old group), but decreased in age group of 15−49 years old (−1.5%). Similarly, the prevalence rate of CRC was higher in all three age groups in 2017 compared to those in 1990 (108.8%, 150.2% and 157.2%, respectively). Interestingly, the death rate of CRC in female significantly decreased in age group of 15−49 and 50−69 years old (−21.6% and −13.0%, respectively), but increased in age group of 70+ years old (19.1%).

Age characteristics in CRC death, incidence and prevalence {#s02.03}
----------------------------------------------------------

The apparent discordancy between younger and older patients with respect to CRC-related death, incidence and prevalence rates prompted us to an age-stratified analysis of trends. According to the data in 2017 at the official website of the IHME, patient data were grouped based on every 5 years of age. From the data discussed above, it was concluded that the incidence of CRC was less than 20/100,000, the prevalence of CRC was less than 100/100,000 and the death rate of CRC was less than 5/100,000 in both male and female in groups younger than 45 years old. However, once the age of patients reached 60 years or older, the incidence of CRC surged to about 100/100,000, the prevalence of CRC surged to about 500/100,000 and the death rate increased to about 30/100,000. Similarly, the prevalence rate of CRC peaked at the age of 75−79 years old with a rate of 791.87/100,000. However, the incidence and death rate increased with age, reaching 229.39/100,000 and 173.06/100,000 in the 90−94 year-old age group (*[Table 1](#Table1){ref-type="table"}*).

Discussion {#s03}
==========

Many changes in society are expected to impact the incidence, prevalence and death of CRC, especially the increasing use of screening methods for CRC and the rapid development of the country. At present, there are little data reported on whether these developments have affected CRC-associated incidence, prevalence and death. The data network platform of IHME is currently the most representative and authoritative continuous data system on the incidence, prevalence and death of CRC all over the world, and data from each involved country are very detailed, including China. The published data set can reflect trends on incidence, prevalence and death of various diseases and present characteristics on different genders, ages and territories. The present study documented these changes and revealed a striking increasing trend of CRC-related incidence, prevalence and death in different age groups. Meanwhile, the prevalence rate of CRC, which is common in Western countries, has been increasing rapidly in Asian countries, including China and South Korea, in recent decades ([@b4],[@b12]-[@b14]). Our data call for programs aimed at reducing the burden of CRC in China.

A secondary analysis was involved in the current study based on data of the official website of IHME between 1990 and 2017.

According to data from IHME, CRC ranked 21st in all causes of death in 1990, while it ranked 11th in 2017. The standardized death rate of CRC increased insignificantly from 9.33/100,000 in 1990 to 10.10/100,000 in 2017. The standardized incidence rate of CRC increased from 12.18/100,000 in 1990 (95% UI: 11.45, 13.41) to 22.42/100,000 in 2017 (95% UI: 21.20, 23.49). CRC is one of the most diagnosed cancers in the United States, the American Cancer Society estimated that there were 140,250 newly diagnosed CRC patients and 50,630 death caused by CRC in 2018 ([@b15]). Similarly, CRC is the first tumor by incidence in European Region (ER) according to the World Health Organization (WHO), with 471,000 new cases each year and a mean death rate of 28.2 per 100,000 population ([@b16]). Besides, CRC incidence and death rate in low- and middle-income countries are increasing ([@b4],[@b17]). It is the fifth most common cancer in sub-Saharan Africa ([@b18]). CRC incidence and death rate in a population are also related to the prevalence of some modifiable risk factors. For CRC, those modifiable risk factors, such as physical activity, smoking, alcohol drinking and diet, have drawn attention ([@b19]). One of the debatable risk factors is fat-intake. Previous study has shown that CRC risk was higher in high fat-intake groups than that in low fat-intake groups ([@b20]). However, a recent systematic review and meta-analysis reported that dietary fats and fatty acids had no effects on the risk of CRC based on a systematic analysis of publications found on PubMed, Web of Science, and the Cochrane library for articles related to dietary fat and the risk of CRC ([@b21]). Independent of exercise and obesity, prolonged sedentary TV watching time, a surrogate for a more inactive lifestyle, was found associated with increased risk of young-onset CRC (yCRC), particularly of rectal cancer ([@b22]). In addition to the above discussed factors, the death rate of CRC is also related to race. Alshareef *et al*. investigated the correlation between race and death among CRC patients in the US during 2007−2014 based on a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) Program. They observed a significant increased risk of death in black and American Indian/Alaska Native patients with CRC compared to white patients ([@b23]). This study showed that although the incidence of CRC has increased significantly, the death rate of CRC did not change significantly. The reason was closely related to the progress of a series of diagnostic and therapeutic measures, such as colonoscopy screening, standardized surgical methods, neoadjuvant radiotherapy and chemotherapy, targeted therapy, and so on ([@b24],[@b25]).

We compared the death and prevalence data of CRC in 2017 to those data in 1990 in three age groups including 15−49 years old, 50−69 years old and 70+ years old. The result revealed a trend of higher prevalence rate of CRC in both genders in all three age groups in 2017, compared to that in 1990, and that the death rate of CRC in patients older than 50 years old increased in both genders. Over the past 20 years, the prevalence of CRC has increased significantly in both males and females in all age groups. According to the incidence data in 2017, the incidence of CRC was less than 20/100,000 in both male and female in groups younger than 45 years old. However, once the age of patients reached 60 or older, the incidence of CRC surged to about 100/100,000, and peaked at the age of 90−94 years old with a rate of 229.39/100,000. CRC is the third leading cause of cancer-related death in the USA ([@b15]), a measurable increase of CRC incidence among individuals younger than age 50, namely yCRC, has been observed, which can also be traced back to 1990 ([@b26]-[@b28]). Besides, an increase of yCRC incidence was also reported. Those patients with yCRC are typically under the age for a routine CRC screening ([@b29]). Routine screening of adults over 50 years old has contributed to a decline in the incidence of CRC in this population ([@b30]). On the other hand, some registries reported a rising incidence of CRC even among young adults at 20−39 years of age, although the absolute incidence in this age group remains far lower than the incidence in adults over 50 years old ([@b31],[@b32]). Randomized controlled trials have shown that screening is associated with a reduction in death rate ([@b33]). Furthermore, CRC screening based on stool testing and flexible sigmoidoscopy has reduced CRC-related death rate by 16% and 22%−31%, respectively ([@b34],[@b35]). The WHO ER examined the association factors in CRC surveillance epidemiology and screening, and found that available resources (as measured by gross national income) appear to be the major factor in the Colorectal Cancer Surveillance Epidemiology and Screening ([@b36]). According to results from studies focused on cost-effectiveness, CRC screening was cost-effective compared with no screening ([@b37]). Recently, the American Center Society has adjusted its guidelines and proposed lowering the age for average risk CRC screening from 50 years old to 45 years old ([@b38]). Further studies are needed to evaluate testing strategies based on age and risk for individuals. It is hoped that by trying to reduce the screening age of colonoscopy to deal with precancerous lesions of CRC as early as possible and to change people's lifestyle, the incidence of CRC can be further reduced through the above two means.

Limitations exist in terms of comprehensiveness and timeliness of information in our research. For instance, we were only able to analyze data on the national prevalence, incidence and death of CRC, other parameters such as geographical characteristics, risk factors of morbidity, the course of disease and other information on CRC were still lacking. In addition, since the data set was a summary of cases reported by different Chinese researchers, the phenomenon of report omission was inevitable, indicating that our research data are underestimated. Further special survey can be carried out focusing on risk factors of CRC to improve the relevant information.

Conclusions {#s04}
===========

Our study presented evidence for a steady increase in CRC incidence and prevalence in China over the past two decades. The prevention and management of known risk factors, such as smoking, alcohol drinking and diet, should be improved through effective national policies. Direct measures and strategies aimed at lowering risk factors and improving treatment should be proposed to stop the growth trend of CRC incidence, and help to decrease the burden of CRC.
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